Examining the Association between Insurance Status as an Access to Care Proxy and 5-year Multiple Myeloma-Specific Survival in US Adults

Advances in multiple myeloma (MM) treatment, including novel agents and autologous stem cell transplant, have led to improved outcomes in survival. However, these treatment regimens are time intensive, complex and length of treatment is indefinite. Supportive care for complications including bone disease, hypercalcemia and anemia is frequently needed. Given this treatment burden, access to care may be influential in survival.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research